Evidence map›Paper›PMID 38888212›Full record

ArticleAnnals of neurology2024

Head-to-Head Comparison of Tau and Amyloid Positron Emission Tomography Visual Reads for Differential Diagnosis of Neurodegenerative Disorders: An International, Multicenter Study.

David N Soleimani-Meigooni, Ruben Smith, Karine Provost, Orit H Lesman-Segev, Isabel Elaine Allen, Miranda K Chen, Hanna Cho, Lauren Edwards, Shorena Janelidze, Renaud La Joie and 15 more

Abstract readMulticenter StudyComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. The Role of Amyloid-β and Tau PET in the New Era of Alzheimer Disease Therapies.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026
    Review
  3. Review
  4. Integrating visual assessments and quantification methods for tau PET staging.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

David N Soleimani-MeigooniMemory and Aging Center, Department of Neurology, University of California, San Francisco, CA, USA.ORCID 0000-0003-4197-3039
Ruben SmithClinical Memory Research Unit, Lund University, Lund, Sweden.
Karine ProvostDepartment of Nuclear Medicine, University of Montreal Hospital Center, Montréal, Canada.
Orit H Lesman-SegevDepartment of Diagnostic Imaging, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel.ORCID 0000-0002-6273-7142
Isabel Elaine AllenDepartment of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA.
Miranda K ChenMemory and Aging Center, Department of Neurology, University of California, San Francisco, CA, USA.
Hanna ChoDepartment of Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea.
Lauren EdwardsMemory and Aging Center, Department of Neurology, University of California, San Francisco, CA, USA.
Shorena JanelidzeClinical Memory Research Unit, Lund University, Lund, Sweden.
Renaud La JoieMemory and Aging Center, Department of Neurology, University of California, San Francisco, CA, USA.
Nidhi MundadaMemory and Aging Center, Department of Neurology, University of California, San Francisco, CA, USA.
Rik OssenkoppeleClinical Memory Research Unit, Lund University, Lund, Sweden.
Erik StomrudClinical Memory Research Unit, Lund University, Lund, Sweden.
Olof StrandbergClinical Memory Research Unit, Lund University, Lund, Sweden.
Amelia StromMemory and Aging Center, Department of Neurology, University of California, San Francisco, CA, USA.
Adam L BoxerMemory and Aging Center, Department of Neurology, University of California, San Francisco, CA, USA.
Jeffrey L DageStark Neuroscience Research Institute, Indiana University School of Medicine, Indianapolis, IN, USA.
Maria Luisa Gorno-TempiniMemory and Aging Center, Department of Neurology, University of California, San Francisco, CA, USA.
Joel H KramerMemory and Aging Center, Department of Neurology, University of California, San Francisco, CA, USA.
Bruce L MillerMemory and Aging Center, Department of Neurology, University of California, San Francisco, CA, USA.
Julio C RojasMemory and Aging Center, Department of Neurology, University of California, San Francisco, CA, USA.
Howard J RosenMemory and Aging Center, Department of Neurology, University of California, San Francisco, CA, USA.
Chul H LyooDepartment of Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea.
Oskar HanssonClinical Memory Research Unit, Lund University, Lund, Sweden.ORCID 0000-0001-8467-7286
Gil D RabinoviciMemory and Aging Center, Department of Neurology, University of California, San Francisco, CA, USA.

Funding

TDP-43 Loss-of-Function: Biology to BiomarkersP01AG019724 · NIA · UNIVERSITY OF PENNSYLVANIA · PI Jennifer Merrilees · 2002 to 2026
$67.2M
Research Education ComponentP30AG062422 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Gil Dan Rabinovici · 2019 to 2026
$36.9M
The Four Repeat Tauopathy Neuroimaging InitiativeR01AG038791 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BOXER, ADAM L. · 2010 to 2020
$18.1M
Progressive Aphasia Cognition Anatomy and ProgressionR01NS050915 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MARIA LUISA GORNO TEMPINI · 2004 to 2026
$11.0M
Reimagining Precision Medicine Approaches to AD DiagnosisR35AG072362 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI POSSIN, KATHERINE LAUREL, RABINOVICI, GIL DAN · 2021 to 2025
$4.8M
Primary Progressive Aphasia: Cognition, Anatomy and ProgressionRF1NS050915 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GORNO TEMPINI, MARIA LUISA · 2022 to 2022
$4.7M
Training program in the neurology of language and neurodegenerative aphasiasK24DC015544 · NIDCD · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GORNO TEMPINI, MARIA LUISA · 2016 to 2025
$1.9M
Proteomics for fluid biomarker discovery in frontotemporal dementiaK23AG059888 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ROJAS-MARTINEZ, JULIO CESAR · 2019 to 2023
$995k
Development of Emergent PET Tracers in Frontotemporal Lobar DegenerationK23AG076960 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI David Nima Soleimani-Meigooni · 2022 to 2026
$951k
Connectome-based spread of neurodegenerative processes in Alzheimer's diseaseK99AG065501 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LA JOIE, RENAUD CHARLES · 2020 to 2021
$253k
Alzheimer's Association AACSF-19-617663Alzheimer's Association SG-23-1061717Alzheimer's Association ZEN-21-848216ERA PerMed ERAPERMED2021-184Knut och Alice Wallenbergs Stiftelse 2017-0383Korea Health Technology R&D Project HU20C0164NIA NIH HHS K23 AG059888NIA NIH HHS K23-AG059888NIA NIH HHS K23 AG076960NIA NIH HHS K23-AG076960NIA NIH HHS K99 AG065501NIA NIH HHS K99-AG065501NIA NIH HHS P01 AG019724NIA NIH HHS P01-AG019724NIA NIH HHS P30 AG062422NIA NIH HHS P30-AG062422NIA NIH HHS R01 AG038791NIA NIH HHS R01-AG038791NIA NIH HHS R35 AG072362NIA NIH HHS R35-AG072362NIDCD NIH HHS K24 DC015544NINDS NIH HHS R01 NS050915NINDS NIH HHS R01-NS050915NINDS NIH HHS RF1 NS050915Regionalt Forskningsstöd 2022-1259Skåne University Hospital Foundation 2020-O000028Swedish Alzheimer Foundation AF-980907Swedish Brain Foundation FO2021-0293Swedish Federal Government under the ALF Agreement 2022-Projekt0080The Parkinson Foundation of Sweden 1412/22Vetenskapsrådet 2022-00775
6 · The paper itself

Abstract

objectiveWe compared the accuracy of amyloid and [

methodsParticipants with FTP-PET, amyloid-PET, and diagnosis of dementia-AD (n = 102), MCI-AD (n = 41), non-AD diseases (n = 76), and controls (n = 20) were included. AD status was determined independent of PET by cerebrospinal fluid or plasma biomarkers. The mean age was 66.9 years, and 44.8% were women. Three readers interpreted scans blindly and independently. Amyloid-PET was classified as positive/negative using tracer-specific criteria. FTP-PET was classified as positive with medial temporal lobe (MTL) binding as the minimum uptake indicating AD tau (tau-MTL+), positive with posterolateral temporal or extratemporal cortical binding in an AD-like pattern (tau-CTX+), or negative. The majority of scan interpretations were used to calculate diagnostic accuracy of visual reads in detecting MCI/dementia with fluid biomarker support for AD (MCI/dementia-AD).

resultsSensitivity of amyloid-PET for MCI/dementia-AD was 95.8% (95% confidence interval 91.1-98.4%), which was comparable to tau-CTX+ 92.3% (86.7-96.1%, p = 0.67) and tau-MTL+ 97.2% (93.0-99.2%, p = 0.27). Specificity of amyloid-PET for biomarker-negative healthy and disease controls was 84.4% (75.5-91.0%), which was like tau-CTX+ 88.5% (80.4-94.1%, p = 0.34), and trended toward being higher than tau-MTL+ 75.0% (65.1-83.3%, p = 0.08). Tau-CTX+ had higher specificity than tau-MTL+ (p = 0.0002), but sensitivity was lower (p = 0.02), driven by decreased sensitivity for MCI-AD (80.5% [65.1-91.2] vs. 95.1% [83.5-99.4], p = 0.03).

interpretationAmyloid- and tau-PET visual reads have similar sensitivity/specificity for detecting AD in cognitively impaired patients. Visual tau-PET interpretations requiring cortical binding outside MTL increase specificity, but lower sensitivity for MCI-AD. ANN NEUROL 2024;96:476-487.

Indexed as

Alzheimer DiseaseCognitive DysfunctionPositron-Emission Tomographytau ProteinsAgedAged, 80 and overAmyloid beta-PeptidesBiomarkersCarbolinesDiagnosis, DifferentialFemaleHumansMaleMiddle AgedNeurodegenerative Diseases7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indoleAmyloid beta-PeptidesBiomarkersCarbolinestau Proteins

Identifiers

PMID38888212
PMCPMC11324380

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.